TrialREVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome
Trial details
- Registry ID
- NCT06914609
- Phase
- Phase 3
Drug research
obudanersen
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as ION582
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman SyndromeNCT06914609 | IONS | Phase 3 | Active not recruiting | 2027-08Estimated |
| CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS)NCT07782827 | IONS | Phase 3 | Recruiting | 2028-05Estimated |
CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS)
Trial details
- Registry ID
- NCT07782827
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |